Zydus Lifesciences bags USFDA approval for advanced prostatic cancer injection
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-11-14 10:00 GMT | Update On 2025-11-14 10:00 GMT
Advertisement
Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection, 1 mg/0.2 mL).
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer.
Leuprolide Acetate injections will be manufactured at the Company’s oncology injectable manufacturing facility at SEZ1, Ahmedabad (‘ALIDAC’). Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept2025). The group now has 427 approvals and has so far filed 487 ANDAs since the commencement of the filing process in FY 2003-04.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.